Microboosting of Atazanavir 300 mg With 50 mg Versus 100mg Ritonavir Daily in HIV-infected Patients: a Pharmacokinetic Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02034838
Recruitment Status : Completed
First Posted : January 14, 2014
Last Update Posted : September 22, 2015
Bristol-Myers Squibb
Information provided by (Responsible Party):
Ottawa Hospital Research Institute

No Study Results Posted on for this Study
  Recruitment Status : Completed
  Primary Completion Date : November 2014
  Study Completion Date : September 2015